Spotlight Innovation Appoints Dr. June Beetler to Board of Directors

URBANDALE, Iowa, May 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that June Beetler, D.O., has been appointed to the Company's Board of Directors. Dr. Beetler joins current board members John M. Krohn, Craig A. Lang, Dr. Sanjeev Agarwal, and Ralph Arthur.

Spotlight Innovation Inc. identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance.

"Dr. Beetler has expansive medical knowledge and hands-on patient care experience, and we are delighted to have such an outstanding practitioner join us," said John Krohn, Spotlight Innovation's President and Chief Executive Officer. "She brings to our boardroom valuable perspective and proven leadership skills, and we look forward to benefiting from her insight and guidance."

"I welcome the opportunity to work with the outstanding business and life science professionals at Spotlight Innovation," said Dr. Beetler. "I'm excited to join the team during this period of growth and to assist in developing the Company's pipeline product candidates."

Dr. Beetler is Board Certified in Pediatrics and has over 20 years of experience in general practice and urgent care settings. Her experience and expertise span general pediatrics, integrative medicine and holistic care. She currently holds a medical license in Florida and practices at St. Petersburg Pediatrics in St. Petersburg, Florida. Before relocating to Florida, Dr. Beetler maintained her own practice, Johnston Pediatric Clinic, P.C., for 18 years, and was a staff physician at Iowa Lutheran Hospital, Iowa Methodist Medical Center, and Mercy Medical Center - Des Moines. As a former biology and chemistry instructor, Dr. Beetler imparted her knowledge to college, high school and secondary school students, and she has mentored medical students on overcoming the day-to-day obstacles encountered in the clinical setting. She earned her Doctor of Osteopathic Medicine at Des Moines University, and completed her residency at Blank Children's Hospital at Iowa Methodist Medical Center.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-appoints-dr-june-beetler-to-board-of-directors-300465188.html

SOURCE Spotlight Innovation Inc.